<DOC>
	<DOCNO>NCT00790374</DOCNO>
	<brief_summary>The purpose study evaluate pharmacodynamic profile safety BN83495 patient prostate cancer disease progression androgen ablative therapy</brief_summary>
	<brief_title>BN83495 Prostate Cancer</brief_title>
	<detailed_description>Evaluate PD profile BN83495 28 day daily oral administration patient locally advance metastatic prostate cancer androgen ablative therapy rise prostatic specific antigen</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Confirmed locally advance metastatic prostate cancer rise prostatespecific antigen ( PSA ) , androgen ablative therapy . Over age 18 . Demonstrated PSA `` biochemical failure '' . Adequate bone marrow hepatic function Luteinizing HormoneReleasing Hormone analogue treatment treat one additional second line endocrine therapy Prior treatment ketoconazole Prior chemotherapy hormone refractory prostate cancer Preexisting cardiac failure and/or clinically significant abnormal ECG Echo</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Pharmacodynamic profile safety BN83495</keyword>
</DOC>